<qa>  What is the primary objective of this phase III study?The primary objective of this phase III study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate 180:60 mg with that of the combination of mefloquine plus artesunate in children and adults with uncomplicated P falciparum malaria. 